Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into certain financing transactions with HT Riverwood Multi-Growth Fund (“Riverwood”), a fund managed by Atlantis Investment Management Limited (“Atlantis”), a leading asset manager, which provides the Company with up to £2 million in cash, £1.5 million of which has been received.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH